ATM and B-cell chronic lymphocytic leukemia: However, a recent study by Rose-Zerilli et al. has shown that ATM mutations rather than BIRC3 deletion and/or mutation had impact on overall and progression-free survival in 11q-deleted CLL patients treated with first-line therapy [51].